Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access |
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc |
Journal website https://www.cardiologyres.org |
Review
Volume 14, Number 5, October 2023, pages 319-333
Subvalvular Aortic Stenosis: Learning From Human and Canine Clinical Research
Figures
Table
Human subvalvular aortic stenosis | Canine subvalvular aortic stenosis | |
---|---|---|
CHD: congenital heart disease; LVOT: left ventricular outflow tract; EOA: effective orifice area; 2D: two-dimensional; 3D: three-dimensional; ECG: electrocardiogram; TXR: thoracic radiographs; TEE: transesophageal echocardiography; MST: median survival time; SAS: subvalvular aortic stenosis; AI: aortic insufficiency. | ||
Prevalence | 0.25% of children, 6% of CHD cases, and 8-30% of LVOT obstruction cases | 0.3% of patients, 4.7% of cardiology patients, and 24% of CHD cases |
Pattern of inheritance | Unknown | Likely autosomal dominant with incomplete penetrance or polygenic |
Diagnosis | Echocardiogram (EOA, 2D, M-mode, Doppler, 3D, and TEE), ECG, and TXR +/- catheterization and bloodwork | Echocardiogram (2D, M-mode, and Doppler) +/- ECG, TXR, and bloodwork |
Therapy/intervention | Resection of fibrous tissue +/- myectomy +/- Konno aortoventriculoplasty | Atenolol (a beta-adrenergic blocker) |
Outcomes | MST is not significantly different from people without SAS; AI, recurrence of fibrous tissue and re-operation | MST is 56 months with atenolol; left-sided congestive heart failure, endocarditis, arrhythmias, exercise intolerance, syncope, and sudden death |
Environment/exposure | Range is similar to nearly identical |